A brief review paper of the efficacy and safety of atorvastatin in early clinical trials

Atherosclerosis
R Bakker-ArkemaD Black

Abstract

Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of dyslipidemic disorders characterized by elevations in low-density lipoprotein cholesterol (LDL-C) and/or triglycerides. Results for patients randomized in early efficacy and safety studies were combined in one database and analyzed. This analysis included a total of 231 atorvastatin-treated patients (131 with hypercholesterolemia (HC), 63 with combined hyperlipidemia (CH), 36 with hypertriglyceridemia (HTG), and 1 with hyperchylomicronemia (Fredrickson Type V)). Patients were treated with a cholesterol-lowering diet (National Institutes of Health National Cholesterol Education Program Step 1 diet or a more rigorous diet) and either 2.5, 5, 10, 20, 40, or 80 mg/day of atorvastatin or placebo. Efficacy was based on percent change from baseline in total cholesterol, total triglycerides, LDL-C, very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (apo B), and non-HDL-C/HDL-C. Safety was assessed in all randomized patients. Atorvastatin seemed to preferentially lower those lipid and lipopro...Continue Reading

References

Jan 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M A Austin
Jul 31, 1990·Biochemical and Biophysical Research Communications·M K ShawB R Krause
Sep 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·G L Vega, S M Grundy
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P T MaM S Brown
Jan 1, 1981·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S Stender, D B Zilversmit
Mar 1, 1996·Journal of Clinical Pharmacology·D M GibsonL R Whitfield
Apr 1, 1996·Journal of Cardiovascular Pharmacology and Therapeutics·T M HeinonenD M Black

❮ Previous
Next ❯

Citations

Mar 30, 1999·Journal of Internal Medicine·N Hoogerbrugge
Jun 20, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Plans-Rubió
Sep 8, 2010·Clinical Pharmacokinetics·Rajesh NarwalSara E Rosenbaum
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Plans-Rubió
Feb 18, 2014·Bioelectrochemistry·Zahra Kamalzadeh, Saeed Shahrokhian
May 13, 2008·Urology·Humberto J Martinez-SuarezGary J Faerber
Apr 9, 2008·European Journal of Internal Medicine·Inbal AvisarEfrat Wolfovitz
Mar 11, 2005·Neurologic Clinics·Ronan J Walsh, Anthony A Amato
Aug 24, 2016·Expert Review of Cardiovascular Therapy·Maria DrakopoulouDimitrios Tousoulis
Mar 28, 2003·The Annals of Pharmacotherapy·Gurhan KadikoyluZahit Bolaman
Jun 11, 2002·Obesity Research·Suzanne Phelan, Thomas A Wadden
Nov 11, 2011·CNS Neuroscience & Therapeutics·Nikhil NihalaniJames L Megna
Aug 4, 1998·Obesity Research·T A WaddenJ L Aber
Jun 20, 2002·Pharmazie in unserer Zeit·Eugen J Verspohl
Dec 22, 1999·Endocrine Reviews·G A Bray, F L Greenway
Apr 27, 1999·British Journal of Pharmacology·I P ConnoleyM J Stock
Jul 27, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·L Campbell, S Rössner
May 20, 2020·Cellular and Molecular Bioengineering·Mahsa KheradmandiAmir M Farnoud
Sep 1, 1999·Alimentary Pharmacology & Therapeutics·A Cahill, M E Lean

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.